Concepedia

Andrew Calinisan

AC

8

Publications

2.6K

Citations

8

H-Index

2019

Active since

Affiliations

Mirati Therapeutics (United States)(Current)

Pfizer (United States)

Andrew Calinisan is an author at Mirati Therapeutics (United States) specializing in medicine, tumor biology, and cancer research.

ORCID

Top concepts

Publications per year

2019–2025

8

Publications

8

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Jill Hallin, Lars D. Engstrom, Lauren Hargis et al. · Cancer Discovery · 2019 · 1.2K citations · Full text

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS <sup>G12D</sup> Inhibitor

Xiaolun Wang, Shelley Allen, James F. Blake et al. · Journal of Medicinal Chemistry · 2021 · 644 citations · Full text

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

Jill Hallin, Vickie Bowcut, Andrew Calinisan et al. · Nature Medicine · 2022 · 465 citations

, , +7

The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy

David M. Briere, Shuai Li, Andrew Calinisan et al. · Molecular Cancer Therapeutics · 2021 · 159 citations · Full text

The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos et al. · Molecular Cancer Therapeutics · 2024 · 22 citations · Full text

, , +17

Rows per page

1–5 of 8